{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:00:51Z","timestamp":1785405651823,"version":"3.56.0"},"reference-count":58,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"22","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The unprecedented expansion of approved oncology therapies has prolonged survival and transformed the prognosis for many patients diagnosed with cancer. However, cancer treatments may be associated with cardiovascular toxicities that manifest through vascular, myocardial, or metabolic pathways, potentially limiting the use of cancer therapeutics and adversely affecting outcomes. Oncology clinical trials provide an important opportunity to evaluate cardiovascular safety signals by generating data on the incidence, timing, and spectrum of toxicities. However, progress has been limited by inconsistent definitions and variable approaches to event characterization. This scientific statement aligns the advances in cardiovascular medicine and cardiovascular clinical trials to provide criteria for systematic selection, rigorous characterization, and adjudication of cardiovascular endpoints in contemporary oncology trials. The proposed framework links drug-specific mechanisms to endpoint selection and standardizes the approach to definitions of adverse cardiovascular events, including heart failure, arrhythmias, myocarditis, and thrombotic events. Definitions of major adverse cardiac events, clinical events, and surrogate endpoints are discussed, along with strategies for alignment with the Common Terminology Criteria for Adverse Events and patient-reported outcomes. Practical guidance is provided for prospective surveillance, decentralized and hybrid clinical trial designs, independent endpoint adjudication, and statistical approaches to competing risks and late-emerging toxicities. By harmonizing cardiovascular endpoint assessment across oncology trials, this scientific statement aims to enhance risk stratification, facilitate regulatory acceptance, and inform clinical decision making, ultimately improving patient safety while supporting innovation in cancer therapeutics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-01647","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:59:27Z","timestamp":1781553567000},"page":"2140-2155","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9935-8904","authenticated-orcid":true,"given":"Ana","family":"Barac","sequence":"first","affiliation":[{"name":"INOVA Heart and Vascular Institute, Fairfax, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-1174","authenticated-orcid":true,"given":"Avirup","family":"Guha","sequence":"additional","affiliation":[{"name":"Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Fleming","sequence":"additional","affiliation":[{"name":"University of Washington, Hans Rosling Center for Population Health, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-3584","authenticated-orcid":true,"given":"Marc","family":"Bonaca","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6497-1098","authenticated-orcid":true,"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[{"name":"Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-9591","authenticated-orcid":true,"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0056-5437","authenticated-orcid":true,"given":"Laleh","family":"Amiri-Kordestani","sequence":"additional","affiliation":[{"name":"US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4650-0513","authenticated-orcid":true,"given":"Vishal","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-8836","authenticated-orcid":true,"given":"Raul","family":"Cordoba","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Jimenez Diaz University Hospital Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-7191","authenticated-orcid":true,"given":"Sara","family":"Hurvitz","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":true,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.08.007"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5953"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06422-1"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.12.010"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.039180"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/RES.0000000000000473"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.09.014"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.041022"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.10.002"},{"key":"e_1_3_11_11_2","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: A subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch E","year":"2021","unstructured":"Kaplovitch E, Eikelboom JW, Dyal L, et al: Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: A subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol 6:21-29, 2021","journal-title":"JAMA Cardiol"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001251"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.033502"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2000052"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915922"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915103"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8034"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040167"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019422"},{"key":"e_1_3_11_20_2","first-page":"e272","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"138","author":"Al-Khatib SM","year":"2018","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, et al: 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 138:e272-e391, 2018 [Erratum: Circulation 138:e419-e420, 2018]","journal-title":"Circulation"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2019.03.002"},{"key":"e_1_3_11_22_2","first-page":"e382","article-title":"2019 ACC\/AHA\/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"140","author":"Kusumoto FM","year":"2019","unstructured":"Kusumoto FM, Schoenfeld MH, Barrett C, et al: 2019 ACC\/AHA\/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 140:e382-e482, 2019","journal-title":"Circulation"},{"key":"e_1_3_11_23_2","unstructured":"US Food and Drug Administration: FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674"},{"key":"e_1_3_11_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2021.01.022"},{"key":"e_1_3_11_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034497"},{"key":"e_1_3_11_27_2","first-page":"391","article-title":"2025 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis","volume":"85","author":"Writing Committee","year":"2025","unstructured":"Writing Committee; Drazner MH, Bozkurt B, et al: 2025 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis. J Am Coll Cardiol 85:391-431, 2025","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_11_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510067"},{"key":"e_1_3_11_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111437"},{"key":"e_1_3_11_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001168"},{"key":"e_1_3_11_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416112"},{"key":"e_1_3_11_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00369"},{"key":"e_1_3_11_33_2","unstructured":"National Cancer Institute: Lead organizations: NCI network trial development and conduct: Protocol development. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development"},{"key":"e_1_3_11_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5403"},{"key":"e_1_3_11_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.111242"},{"key":"e_1_3_11_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001032"},{"key":"e_1_3_11_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.08.045"},{"key":"e_1_3_11_38_2","unstructured":"National Archives: 21 CFR \u00a7314.510: Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. https:\/\/www.ecfr.gov\/current\/title-21\/part-314\/section-314.510"},{"key":"e_1_3_11_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2019.04.010"},{"key":"e_1_3_11_40_2","unstructured":"US Food and Drug Administration: Core patient-reported outcomes in cancer clinical trials: Guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials"},{"key":"e_1_3_11_41_2","unstructured":"International Consortium for Health Outcomes Measurement: When healthcare listens lives change. https:\/\/www.ichom.org"},{"key":"e_1_3_11_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.09.007"},{"key":"e_1_3_11_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.001767"},{"key":"e_1_3_11_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2249"},{"key":"e_1_3_11_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz871"},{"key":"e_1_3_11_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00215-0"},{"key":"e_1_3_11_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11916"},{"key":"e_1_3_11_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14286"},{"key":"e_1_3_11_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00151-2"},{"key":"e_1_3_11_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2014.10.003"},{"key":"e_1_3_11_51_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001174"},{"key":"e_1_3_11_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"e_1_3_11_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.08.743"},{"key":"e_1_3_11_54_2","unstructured":"US Food and Drug Administration. IND application reporting: Safety reports. https:\/\/www.fda.gov\/drugs\/investigational-new-drug-ind-application\/ind-application-reporting-safety-reports"},{"key":"e_1_3_11_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02320"},{"key":"e_1_3_11_56_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.046048"},{"key":"e_1_3_11_57_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.067786"},{"key":"e_1_3_11_58_2","unstructured":"US Food and Drug Administration: Digital health technologies for remote data acquisition in clinical investigations 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/digital-health-technologies-remote-data-acquisition-clinical-investigations"},{"key":"e_1_3_11_59_2","unstructured":"US Food and Drug Administration: Artificial intelligence\u2013enabled medical devices 2025. https:\/\/www.fda.gov\/medical-devices\/software-medical-device-samd\/artificial-intelligence-enabled-medical-devices"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-01647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:59:29Z","timestamp":1785362369000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-01647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":58,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,8,1]]}},"alternative-id":["10.1200\/JCO-25-01647"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-01647","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"2025-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}